Cutera® Announces AviClear® Investor Webinar

Rhea-AI Summary

Cutera announced an investor webinar to present AviClear, the first FDA-cleared energy device for treating inflammatory acne, on June 20, 2024, at 11 a.m. PDT. The session will cover clinical data, market potential, future studies, and user experiences. Key speakers include CEO Taylor Harris, CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, and dermatologists Dr. David J. Goldberg and Dr. Sonia Batra. The event will conclude with a live Q&A session for analysts and investors. Participants can join via the provided link or phone numbers. A replay will be available on Cutera’s website the next day.

Positive

• AviClear is FDA-cleared for long-term treatment of mild, moderate, and severe inflammatory acne.
• The webinar will discuss substantial clinical data and real-world user experiences.
• Cutera has assembled a credible panel of experts, including top executives and prominent dermatologists.
• Market opportunity for AviClear could be significant considering the prevalence of acne.
• Future clinical studies indicate ongoing investment in product development and innovation.

Negative

• No specific financial updates or new revenue streams were announced in the PR.
• The PR lacks detailed preliminary market performance or sales data for AviClear.
• Webinar success is dependent on investor interest and participation, which is uncertain.

BRISBANE, Calif.--(BUSINESS WIRE)-- CUTERA, INC. (Nasdaq: CUTR), a leading provider of aesthetic and dermatology solutions, announced today that it will hold an investor webinar at 11 a.m. PDT on June 20, 2024, to present an overview of AviClear, the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne. The webinar will include a review of clinical data, market opportunity, future clinical studies, and real-world user experience.

The AviClear Investor Webinar will feature presentations by Cutera CEO Taylor Harris, EVP and CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, as well as leading dermatologists David J. Goldberg, MD, JD, and Sonia Batra, MD, MSc, MPH. The presentation will be followed by a live Q&A session for analysts and investors.

Participants can join the AviClear Investor Webinar at cutera.co/aviclearinvestor.

If participants prefer to join by telephone, they may dial Canada/USA Toll Free: 1-844-763-8274 or +1-647-484-8814. It is recommended that you call in 10 minutes prior to the scheduled start time and ask to join the Cutera webinar.

A replay will be available on Cutera’s Investor Relations website the following day.

About Cutera, Inc.

Cutera is a leading provider of aesthetic and dermatology solutions for practitioners worldwide. For over 25 years, Cutera strives to improve lives through medical aesthetic technologies that are driven by science and powered through partnerships. For more information, call 1-888-4-CUTERA or visit Cutera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240607162672/en/

Investor Relations Contact:

Shelby Eckerman, VP, Finance

IR@Cutera.com

Source: Cutera, Inc.

FAQ

What is AviClear by Cutera?

AviClear is the first FDA-cleared energy device for the long-term treatment of mild, moderate, and severe inflammatory acne.

When is the AviClear investor webinar?

The AviClear investor webinar is scheduled for 11 a.m. PDT on June 20, 2024.

Who will present at the AviClear investor webinar?

Presenters include Cutera CEO Taylor Harris, CTO Michael Karavitis, SVP of Global Marketing Steve Kreider, and dermatologists Dr. David J. Goldberg and Dr. Sonia Batra.

How can investors join the AviClear webinar?

Investors can join via the link cutera.co/aviclearinvestor or by dialing Canada/USA Toll-Free: 1-844-763-8274 or +1-647-484-8814.

What topics will be covered in the AviClear investor webinar?

The webinar will cover clinical data, market opportunity, future clinical studies, and real-world user experience of AviClear.